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Background: Antithrombotic therapy after bioprosthetic aortic valve replacement (AVR) is a debated issue. AVR is frequent given the high 
prevalence of aortic stenosis. The absence of consensus highlights the need for an evaluation of clinical practices.
methods: Antithrombotic therapy after bioprosthetic AVR was prospectively studied in 434 patients between January and April 2011 in 14 centres. 
Patients previously treated with vitamin K antagonists (VKA) were excluded. Mean age was 75±9 years, 58% were male and 33% had coronary artery 
disease. Surgery was performed for aortic stenosis in 87% of cases and was combined with coronary artery bypass grafting (CABG) in 23% of cases.
results: In-hospital antithrombotic treatment was : aspirin alone in 65% of cases; VKA alone in 9%; VKA+ aspirin in 19%; and neither VKA nor 
aspirin in 7%.Factors that impacted the prescription of VKA were: coronary disease (p<0.001), associated CABG (p<0.007) and post-operative 
supraventricular arrhythmias (p<0.007). The strongest factor was the centre effect (p<0.0001) (Figure 1). There was no relationship between the 
prescription of VKA and in-hospital thromboembolic complications (p<0.21) or bleeding (p<0.31).
conclusions: This multicentre prospective study shows that VKA are prescribed in only 28% of patients after bioprosthetic AVR, despite 
recommendations in Europe. VKA prescription seems to be mainly related to the centre effect. Homogenization of clinical practices is therefore 
needed.
 
